Trial challenges COPD drug fears

Tiotropium cuts mortality in COPD patients by 16 per cent compared with placebo, results of a 5,993-patient study show.

The long-acting anticholinergic drug, marketed as Spiriva, reduced exacerbations, delayed time to first exacerbation and cut the risk of exacerbations leading to hospital admission.

However, it failed to statistically significantly reduce decline in FEV1 after four years, the trial's primary endpoint.

The finding of reduced mortality contrasts with a recent JAMA analysis suggesting anticholinergics raise CVD risk.

  • NEJM 2008; 359: 1,543-54.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

£20 notes spread out

VAT trap for PCNs could strip millions of pounds from general practice

Tens of millions of pounds could be stripped from general practice because work carried...

Talking General Practice logo

Podcast: Is the BMA representing GPs effectively, why GPs face a pension tax hit, and views on the workload crisis

In our regular news review the team discusses representation of GPs, a new survey...

Man sleeping

NICE guidance on insomnia backs app to replace sleeping pills

Hundreds of thousands of people with insomnia could be offered treatment via a mobile...

Health worker prepares a dose of COVID-19 vaccine

JCVI backs autumn COVID-19 booster campaign for high-risk adults and NHS staff

Frontline health and social care staff and adults at increased risk of severe illness...

GP consultation

Government accused of 'misleading' claims on general practice workforce

GP leaders have accused the government of making misleading claims about the general...

Consulting room door

LMC calls for enhanced access to be scrapped after abuse forces practice to close reception

A Midlands LMC has backed a practice forced to close its reception desk after abuse...